| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/arcus-biosciences-rcus-moves-78-higher-will-strength-last","as_of":"2026-04-22T13:12:40.941923+00:00","canonical_url":"https://www.nasdaq.com/articles/arcus-biosciences-rcus-moves-78-higher-will-strength-last","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/arcus-biosciences-rcus-moves-78-higher-will-strength-last","article_chars":2410,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_b28e310aee354dd0","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/arcus-biosciences-rcus-moves-78-higher-will-strength-last","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-22T13:17:20.535559+00:00","extraction_method":"trafilatura","fetched_description":"Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.","fetched_title":"Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last? | Nasdaq","final_url":"https://www.nasdaq.com/articles/arcus-biosciences-rcus-moves-78-higher-will-strength-last","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/arcus-biosciences-rcus-moves-78-higher-will-strength-last","source_event_id":"evt_fd7225635527","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"035a955e2ca9d695","kind":"new_listings","published_at":"2026-04-22T11:34:00+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":[],"entities":[{"asset_class":"equity","name":"Arcus Biosciences, Inc.","relevance":"high","symbol":"RCUS","type":"company"},{"asset_class":"equity","name":"Qiagen","relevance":"low","symbol":"QGEN","type":"company"}],"event_type":"price_action","information_gaps":["No specific date for the \u201clast trading session\u201d is provided.","The article does not quantify how much trading volume exceeded the average (only that it was higher-than-average).","No details are provided on which pipeline candidates or which clinical trial stages/indications drove the investor confidence claim.","The article references \u201clatest trend in earnings estimate revisions\u201d but provides only that the consensus EPS estimate remained unchanged over the last 30 days; it does not provide the prior level or any other revision metrics.","The article does not provide forward-looking performance beyond the general statement that price may not keep rising without estimate revision trends."],"key_facts":["RCUS shares ended the last trading session 7.8% higher at $24.52.","The session volume was higher than average, with a higher-than-average number of shares traded.","RCUS is described as having gained 6.2% over the past four weeks.","The article attributes the price rise to growing investor confidence in Arcus Biosciences\u2019 pipeline candidates evaluated in monotherapy and combination studies across various clinical stages targeting cancer indications.","The article states Arcus Biosciences is expected to post a quarterly loss of $0.92 per share in its upcoming report, a year-over-year change of +19.3%.","The article states revenues are expected to be $14 million, down 50% from the year-ago quarter.","The article says the consensus EPS estimate for the quarter has remained unchanged over the last 30 days.","The article states the stock carries a Zacks Rank #3 (Hold).","The article mentions Qiagen (QGEN) finished the last trading session 2.3% lower at $40.1 and has a Zacks Rank #4 (Sell)."],"numeric_claims":[{"label":"RCUS last session % change","value":"7.8%"},{"label":"RCUS last session close","value":"$24.52"},{"label":"RCUS past four weeks % gain","value":"6.2%"},{"label":"Expected quarterly loss per share (Arcus)","value":"-$0.92"},{"label":"Year-over-year change in expected EPS (Arcus)","value":"+19.3%"},{"label":"Expected revenues (Arcus)","value":"$14 million"},{"label":"Year-over-year change in expected revenues (Arcus)","value":"-50%"},{"label":"Consensus EPS estimate change over last 30 days (Arcus)","value":"unchanged (0%)"},{"label":"Qiagen last session % change","value":"-2.3%"},{"label":"Qiagen last session close","value":"$40.1"},{"label":"Qiagen return over past month","value":"3.9%"}],"primary_claim":"RCUS ended the last trading session up 7.8% at $24.52 on higher-than-average volume, while its consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days.","relevance_score":0.62,"sentiment":"mixed","source_quality":"high","summary":"Arcus Biosciences (RCUS) rose 7.8% to $24.52 on higher-than-average trading volume in the last session. The article links the move to investor confidence in its clinical pipeline, but notes consensus EPS estimate revisions have been unchanged over the last 30 days, suggesting limited near-term follow-through absent estimate changes.","topics":["stock price move","trading volume","clinical pipeline confidence","earnings estimate revisions","Zacks Rank"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.","tickers":["RCUS"],"title":"Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?","url":"https://www.nasdaq.com/articles/arcus-biosciences-rcus-moves-78-higher-will-strength-last"}... |